The FDA advised that U.S. patients who are now taking Carbolith to stay on the drug for now, but consult with a physician as soon as possible to switch to another therapy.

U.S. consumers who purchased the antipsychotic compound via the Internet to treat manic depressive disorder could experience lowered lithium blood levels, the agency warned, prompting a whole range of side effects.

These include a worsening of an individual's manic depressive illness or related symptoms, such as motor hyperactivity, delusions of grandeur, depression and suicidal thoughts.

Moreover, once patients switch over to a lithium carbonate drug with an adequate amount of the active ingredient, the sudden change could cause toxicity in patients, resulting in physical problems like hand tremors, drowsiness or blurred vision, the FDA said.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.